The present invention provides a detection reagent and therapeutic target for B cell tumor after targeted therapy and related applications. The reagent composition comprises 3 groups of antibodies, with the first group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD24 an antibody, an anti-CD20 antibody, an anti-CD81 antibody, an anti-CD45 antibody; the second group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD20 antibody, an anti-CD72 antibody, an anti-CD45 antibody; and the third group of antibodies including an anti-cytoplasmic CD79a antibody. The reagent composition of the present invention can be applied for the detection of B-lymphocyte tumors after targeted therapy by flow cytometry.

Disclosed herein are certain sets of antibody-fluorophore pairs comprising antibodies that specifically bind target antigens, the sets of antibody-fluorophore pairs thereby allowing visualization and quantification of a plurality of target antigens in a biological sample using multispectral tissue slide scanners. Also disclosed herein are methods of using such antibody-fluorophore pairs, and reagents related thereto.

Disclosed herein are certain sets of antibody-fluorophore pairs comprising antibodies that specifically bind target antigens, the sets of antibody-fluorophore pairs thereby allowing visualization and quantification of a plurality of target antigens in a biological sample using multispectral tissue slide scanners. Also disclosed herein are methods of using such antibody-fluorophore pairs, and reagents related thereto.

The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.

The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.

The present invention relates to an in-vitro method for detecting anti-erythrocyte antibodies in a sample, comprising at least the following steps: a) bringing the sample into contact with one or more test erythrocytes or a suspension of one or more test erythrocytes having a known phenotype, under conditions likely to induce hemagglutination, so as to obtain a reaction mixture; b) bringing the reaction mixture into contact with a solid substrate containing a plurality of defined adsorption areas which have previously fixed antibodies or antibody fragments capable of binding antigenic determinants present on the one or more test erythrocytes; c) ascertaining the presence or absence of a hemagglutination reaction in at least one of the adsorption areas so as to detect the presence or absence of anti-erythrocyte antibodies in the sample; the steps a) and b) being carried out separately or simultaneously.

The present invention relates to an in-vitro method for detecting anti-erythrocyte antibodies in a sample, comprising at least the following steps: a) bringing the sample into contact with one or more test erythrocytes or a suspension of one or more test erythrocytes having a known phenotype, under conditions likely to induce hemagglutination, so as to obtain a reaction mixture; b) bringing the reaction mixture into contact with a solid substrate containing a plurality of defined adsorption areas which have previously fixed antibodies or antibody fragments capable of binding antigenic determinants present on the one or more test erythrocytes; c) ascertaining the presence or absence of a hemagglutination reaction in at least one of the adsorption areas so as to detect the presence or absence of anti-erythrocyte antibodies in the sample; the steps a) and b) being carried out separately or simultaneously.

A time-resolved fluorescence and chromogenic dual-signal test strip for estrogen is based on the principle of immune recognition and fluorescence resonance energy transfer. In time-resolved fluorescence mode, estrogen-BSA-persistent luminescence particle complex is the fluorescence donor, and colloidal gold modified with estrogen monoclonal antibody is the fluorescence receptor, which is also chromogenic signal unit in the chromogenic mode. The photos of strips in both modes are obtained with smart phones. The time-resolved fluorescence intensity of the test strip test zone is positively correlated with estrogen content, and the chromogenic intensity is negatively correlated with estrogen content. The competitive time-resolved fluorescence and chromogenic dual-signal immunochromatographic test strips can accurately and quickly detect estrogen and estrogen-like compounds.

A time-resolved fluorescence and chromogenic dual-signal test strip for estrogen is based on the principle of immune recognition and fluorescence resonance energy transfer. In time-resolved fluorescence mode, estrogen-BSA-persistent luminescence particle complex is the fluorescence donor, and colloidal gold modified with estrogen monoclonal antibody is the fluorescence receptor, which is also chromogenic signal unit in the chromogenic mode. The photos of strips in both modes are obtained with smart phones. The time-resolved fluorescence intensity of the test strip test zone is positively correlated with estrogen content, and the chromogenic intensity is negatively correlated with estrogen content. The competitive time-resolved fluorescence and chromogenic dual-signal immunochromatographic test strips can accurately and quickly detect estrogen and estrogen-like compounds.

The present application discloses an electrochemiluminescence (ECL) immunosensor. The ECL immunosensor includes an electrode modified by a nanocomposite comprising a mixture of carbon nanochips (CNCs); iron oxide (Fe.sub.3O.sub.4); and nafion (NAF). The electrode is a screen-printed electrode which further is a carbon screen-printed electrode (SPE). The carbon screen-printed electrode (SPE) is a mesoporous carbon screen-printed electrode (SPE). Ru(bpy).sub.3Cl.sub.2.6H.sub.2O is a luminophore and TPrA is a coreactant of the luminophore.